gbola amusa md cfa head hc research
sale trade et
sale trade et
viral news announc posit data
highlight week decemb januari buy chardan top pick
year-end corpor updat report posit interim data phase trial
gene therapi gt wet announc plan expand addit retin indic
proqr buy receiv track design ftd fda rna-bas oligonucleotid
usher syndrom type expect commenc enrol phase i/ii studi continu believ
proqr potenti becom signific competitor oligonucleotid therapeut market amicu
therapeut neutral initi phase i/ii trial batten diseas amicu
batten diseas gt asset phase i/ii trial advanc follow
preclin
look forward januari januari januari allianc regen medicin host cell
 gene therapi state industri brief san francisco ca repres follow compani
present privat autolu therapeut unrat neutral precis
bioscienc privat audent neutral unrat bluebird bio unrat
januari pm et intrexon corp unrat hold investor meet compani debut
portfolio wholly-own subsidiari intrexon januari annual t-cell lymphoma
forum held la jolla ca present compani includ rate
weekli price move vivo genet medicin aav srna vivo gene edit
mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
januari non-deal roadshow meiragtx san francisco healthcar week ceo cdo ir sf
analyst taylor feehley phd moder kol call featur patent attorney discuss ip issu
microbiom medicin space issu may relev genet medicin buy
analyst gbola amusa md cfa moder panel titl improv cell therapi via gener
technolog summit
prqr updat clinic program januari
proqr rna-bas candid usher syndrom type receiv track design ftd
fda proqr previous receiv fda clearanc ind expect commenc enrol
phase i/ii studi
compani also plan advanc rna-bas oligonucleotid treatment rare ophthalm
diseas leber congenti amaurosi lca phase ii/iii clinic studi
maintain buy rate price target continu believ proqr
potenti becom signific competitor oligonucleotid therapeut market
buy report data chardan top pick januari
pleas refer import disclosur inform regul analyst certif found page report
provid year-end corpor updat report posit data guidanc across multipl program
includ gt current phase trial wet
regard develop patient treat cohort continu remain free anti-vegf
inject month mean intraocular protein express cohort higher cohort
month cohort mean best correct visual acuiti bcva improv letter mean central retin
thick crt decreas micron baselin month fda provid clearanc expans
phase studi phase iia studi plan expand addit retin
believ may see profit time compani expect end mm
cash cash equival market secur exclud project commerci revenu novarti
rate zolgensma anticip approv may
genet medicin news decemb januari
prqr buy ad nasdaq biotechnolog index decemb
unrat clarifi exclus right asset includ sleep beauti tcr car-t decemb
wenzhou medic univers publish review clinic applic aav genom edit decemb
privat file term mm ipo decemb
prqr buy receiv track design fda rp januari
opht neutral elect calvin robert board director effect januari januari
unrat partner aldevron privat gmp-grade plasmid dmd gt januari
arct buy announc intent develop lunar mrna therapi treat otcd januari
nv nr publish durabl respons juliet kymriah trial adult r/r dlbcl januari
unrat appoint robert meyer board director effect immedi januari
unrat announc suvodirsen dmd clinic trial select fda innov trial program januari
unrat highlight compani progress expect mileston januari
unrat partner arbor privat gene edit cf diseas januari
arbor privat appoint paul meister board director januari
arbor privat announc public scienc note dec issu januari
bold neutral appoint eric mosbrook svp chief commerci offic januari
avid privat publish review articl oligonucleotid target rna januari
stride privat appoint sapan shah ceo member board director januari
celg unrat enter merger agreement bn acquisit bm unrat januari
neutral initi phase i/ii trial aav gt batten diseas januari
studi evalu safeti efficaci singl intrathec administr gt
children year old batten diseas patient enrol dose group
low-dos group high-dos group evalu group
studi dose patient seriou advers event report month observ period
compani similar trial batten diseas alreadi progress data readout
anticip
axon neutral highlight compani progress expect mileston januari
umrx unrat highlight compani progress expect mileston januari
umrx unrat announc cfo christiana stamouli step effect januari januari
arct buy appoint andrew sassin serv interim cfo cfo effect januari januari
page
neubas tx privat revers merg ohrp unrat advanc peptid nucleic acid platform januari
brammer privat hire steve falcon chief qualiti offic appoint cfo januari
sqz privat appoint oliv rosen md chief medic offic januari
unrat appoint william koschak cfo effect januari januari
unrat provid year-end updat program includ multitaa cell cancer januari
unrat announc posit top-line data phase i/ii studi gsdia januari
cohort gc/kg phase i/ii trial gt express
gene show improv glucos control increas time hypoglycemia
fast gsdia patient patient demonstr clinic meaning improv time
safeti profil show infusion-rel advers event treatment-rel seriou advers event
advers event grade patient mild elev alanin aminotransferas level
patient cohort gc/kg expect dose januari
neutral announc boehring ingelheim privat exercis option right target januari
crsp buy announc fda ftd collabor unrat scd januari
ciri publish genom edit use viral-deriv nanoblad load januari
rgl nr announc advers find adpkd new mous toxic studi januari
mdco buy sell addit mm convert note top previou mm januari
poseida tx privat file term mm ipo januari
poseida tx privat appoint catherin mackey marcea bland lloyd board januari
compani mention report
page
page
rate price target histori toolgen inc
creat bluematrix
rate price target histori arbutu biopharma corpor abu
creat bluematrix
rate price target histori inc
creat bluematrix
page
rate price target histori appli genet corpor agtc
creat bluematrix
rate price target histori inc
rate price target histori arcturu therapeut ltd arct
creat bluematrix
creat bluematrix
page
rate price target histori arrowhead inc
rate price target histori axov scienc ltd axon
creat bluematrix
rate price target histori crispr ag crsp
creat bluematrix
creat bluematrix
page
rate price target histori inc
rate price target histori inc
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori iovanc inc
rate price target histori medicin compani mdco
creat bluematrix
rate price target histori miragen therapeut
creat bluematrix
creat bluematrix
page
rate price target histori nightstar therapeut nite
rate price target histori inc
creat bluematrix
rate price target histori inc
creat bluematrix
creat bluematrix
page
rate price target histori ophthotech opht
rate price target histori proqr nv prqr
creat bluematrix
creat bluematrix
rate price target histori uniqur qure
creat bluematrix
page
rate price target histori inc
rate price target histori inc rgl
creat bluematrix
rate price target histori regenxbio inc
creat bluematrix
creat bluematrix
page
rate price target histori gensight biolog sight fp
rate price target histori
creat bluematrix
rate price target histori vascular biogen ltd vblt
creat bluematrix
creat bluematrix
page
